Compare Constellation Energy Corporation (CEG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Constellation Energy Corporation vs Twist Bioscience Corp — how do they compare? Constellation Energy Corporation trades at $282.92 (market cap $98.63B), while Twist Bioscience Corp trades at $121.81 (market cap $7.72B). The key difference: Constellation Energy Corporation is far larger — about 12.8× Twist Bioscience Corp's market cap, and Constellation Energy Corporation pays a 0.61% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| CEG | TWST | |
|---|---|---|
Market Cap | $98.63B | $7.72B |
Sector | Energy | Health |
52-Week High | $403.95 | $124.88 |
52-Week Low | $236.50 | $24.16 |
Enterprise Value | $122.63B | $7.65B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Constellation Energy (CEG) is trading at $281.84, up 4.22% today, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with Q2 2026 EPS of $2.55 beating expectations by 11.4%, and raised 2026 guidance. Recent news highlights nuclear power contracts with major tech companies driving growth. Technical indicators show bullish momentum with support at $277 and resistance at $282.
CEG presents a compelling investment case with strong earnings momentum, AI-driven power demand tailwinds, and 70% analyst buy ratings. Risks include execution of nuclear capacity expansion and potential regulatory changes. The consensus price target of $332.13 suggests 18% upside potential from current levels.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Constellation Energy Corporation
Constellation is the largest producer of carbon-free energy in the U.S. and a leading nuclear power plant operator. It provides sustainable electricity to millions of residential, public, and industrial customers.
Read more on CEG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
